"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- Advise patients to discontinue LYSODREN in the case of shock or severe trauma and contact their healthcare provider immediately.
- Advise patients to tell their healthcare provider of any planned surgeries.
- Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS and Use in Specific Populations].
- Advise females of reproductive potential to use effective contraception during treatment and after discontinuation of treatment for as long as instructed by their healthcare provider [see Use in Specific Populations].
- Advise females who are nursing not to breastfeed during treatment with LYSODREN [see Use In Specific Populations].
Last reviewed on RxList: 3/28/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Lysodren Information
Lysodren - User Reviews
Lysodren User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.